Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 6/20 | 0.42 |
| ▸ | WNT3A | P56704 | 6/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | BRD1 | O95696 | 1/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482269 | 1.00 | CTNNB1 (0.42) | CTNNB1WNT3AHDAC3HDAC4HDAC1 | |
| SCHEMBL13814476 | 0.90 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL18713950 | 0.86 | CTNNB1 (0.43) | CTNNB1WNT3AHDAC3HDAC4HDAC1 | |
| SCHEMBL2629597 | 0.83 | HDAC3 (0.45) | CTNNB1WNT3AHDAC3HDAC4HDAC1 | |
| SCHEMBL8209755 | 0.82 | PTGS1 (0.49) | USP2ALDH1A1GAAPKMHPGD | |
| SCHEMBL23123676 | 0.81 | HDAC3 (0.43) | CTNNB1WNT3AHDAC3HDAC4HDAC1 | |
| SCHEMBL29757900 | 0.81 | HDAC3 (0.43) | CTNNB1WNT3AHDAC3HDAC4HDAC1 | |
| SCHEMBL13369290 | 0.80 | PTGS1 (0.38) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14177758 | 0.80 | HDAC4 (0.39) | HDAC4HDAC2HDAC8CLK1DYRK1A | |
| SCHEMBL12997915 | 0.79 | HDAC3 (0.44) | CTNNB1WNT3AHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CURZA GLOBAL, LLC. | 2023-09-07 | — | — | US | disclosed |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | NEUROPORE THERAPIES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-20210024539-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2021-01-28 | — | — | US | disclosed |
| US-20200308163-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| WO-2017108723-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-8163787-B2 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | CLARK RICHARD | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CLPP, RPN2, MPO | CTNNB1 4110/4885WNT3A 4502/4885HDAC3 1438/4885 |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | CTNNB1 619/4885WNT3A 919/4885HDAC3 826/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | CTNNB1 619/4885WNT3A 919/4885HDAC3 826/4885 |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | H1-10, H1-0, H1-2 | CTNNB1 174/4885WNT3A 211/4885HDAC3 63/4885 |
| US-20200308163-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | CTNNB1 4419/4885WNT3A 4341/4885HDAC3 536/4885 |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | TLR2, TLR4, TLR3 | CTNNB1 4304/4885WNT3A 4116/4885HDAC3 1146/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | CTNNB1 619/4885WNT3A 919/4885HDAC3 826/4885 |
| US-20210024539-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | TLR2, TLR4, TLR3 | CTNNB1 4304/4885WNT3A 4116/4885HDAC3 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.